Dr. Erika Maestas
Claim this profileUniversity of New Mexico Cancer Center
Studies Pancreatic Cancer
Studies Pancreatic Carcinoma
4 reported clinical trials
8 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
BRCA1 positive
BRCA2 positive
2Pancreatic Carcinoma
BRCA1 positive
BRCA2 positive
PALB2 positive
Affiliated Hospitals
Clinical Trials Erika Maestas is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
More about Erika Maestas
Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Erika Maestas has experience with
- Olaparib
- Cisplatin
- Radiation Therapy
- MFOLFIRINOX
- MFOLFOX
- Nivolumab
Breakdown of trials Erika Maestas has run
Pancreatic Cancer
Pancreatic Carcinoma
Parotid Gland Cancer
Oropharyngeal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Erika Maestas specialize in?
Erika Maestas focuses on Pancreatic Cancer and Pancreatic Carcinoma. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are BRCA1 positive.
Is Erika Maestas currently recruiting for clinical trials?
Yes, Erika Maestas is currently recruiting for 3 clinical trials in Albuquerque New Mexico. If you're interested in participating, you should apply.
Are there any treatments that Erika Maestas has studied deeply?
Yes, Erika Maestas has studied treatments such as Olaparib, Cisplatin, Radiation Therapy.
What is the best way to schedule an appointment with Erika Maestas?
Apply for one of the trials that Erika Maestas is conducting.
What is the office address of Erika Maestas?
The office of Erika Maestas is located at: University of New Mexico Cancer Center, Albuquerque, New Mexico 87106 United States. This is the address for their practice at the University of New Mexico Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.